Valiant Laboratories Past Earnings Performance
Past criteria checks 1/6
Valiant Laboratories's earnings have been declining at an average annual rate of -37.7%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been declining at an average rate of 9.8% per year. Valiant Laboratories's return on equity is 24.3%, and it has net margins of 6.3%.
Key information
-37.7%
Earnings growth rate
-53.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -9.8% |
| Return on equity | 24.3% |
| Net Margin | 6.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Valiant Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4,097 | 256 | 71 | 0 |
| 30 Sep 23 | 4,400 | 372 | 70 | 0 |
| 31 Mar 23 | 5,009 | 435 | 70 | 0 |
| 31 Mar 22 | 3,124 | 341 | 33 | 0 |
Quality Earnings: VALIANTLAB has a large one-off gain of ₹57.6M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: VALIANTLAB's current net profit margins (6.3%) are lower than last year (9.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if VALIANTLAB's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: VALIANTLAB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: VALIANTLAB had negative earnings growth (-37.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.3%).
Return on Equity
High ROE: VALIANTLAB's Return on Equity (24.3%) is considered high.